Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 8, 2012

mAb Therapeutics for Alzheimer Disease Unlikely to Be Fully Successful, According to GEN Poll

  • Maybe mAb therapeutics will someday be the answer to treating Alzheimer’s disease, but respondents to a recent GEN poll are yet to be convinced. A majority of respondents (52.4%) said they did not see that happening, compared with 28.6% that did.

    With the global market for neurodegenerative treatments expected to exceed $43.4 billion by 2015, according to Global Industry Analysts, companies are pursuing biologics like mAb therapeutics as drug candidates for Alzheimer and other neurodegenerative disorders and moving away from small molecule drugs and peptides, following early- and late-stage drug failures. However, few to no drugs have emerged that impact either the cause or progression of diseases of the central nervous system.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »